Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer Meeting Abstract
| Authors: | Cassier, P. A.; Van Laethem, J. L.; Borbath, I.; Macarulla, T.; Geboes, K. P.; Lambert, A.; Prenen, H.; Mitry, E.; Blanc, J. F.; Feliu, J.; Cid, R. A. P.; Jimenez, I. G.; Smith, K. E.; Nordbladh, K.; de Coana, Y. P.; O'Reilly, E. M.; Jimenez, D. G.; Ambarkhane, S. V.; Ellmark, P.; Beatty, G. L.; OPTIMIZE-1 Investigators |
| Abstract Title: | Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | 2624 |
| Language: | English |
| ACCESSION: | WOS:001525785300001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.2624 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
